Viewing Study NCT01745120

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:13 AM
Ignite Modification Date: 2026-02-24 @ 1:50 PM
Study NCT ID: NCT01745120
Status: COMPLETED
Last Update Posted: 2019-05-08
First Post: 2012-12-06
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants
Sponsor: Genetix Biotherapeutics Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None β-thalassemia Major View
Keywords:

Keywords

Keyword Brief Keyword Text View
None gene therapy View
None β thalassemia View
None hemoglobin View
None anemia View
None CD34 View